SG11201707705UA - Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) - Google Patents
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)Info
- Publication number
- SG11201707705UA SG11201707705UA SG11201707705UA SG11201707705UA SG11201707705UA SG 11201707705U A SG11201707705U A SG 11201707705UA SG 11201707705U A SG11201707705U A SG 11201707705UA SG 11201707705U A SG11201707705U A SG 11201707705UA SG 11201707705U A SG11201707705U A SG 11201707705UA
- Authority
- SG
- Singapore
- Prior art keywords
- tim
- directed against
- antibodies directed
- cell immunoglobulin
- mucin protein
- Prior art date
Links
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 title 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000015728 Mucins Human genes 0.000 title 1
- 108010063954 Mucins Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141353P | 2015-04-01 | 2015-04-01 | |
| PCT/US2016/025532 WO2016161270A1 (en) | 2015-04-01 | 2016-04-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707705UA true SG11201707705UA (en) | 2017-10-30 |
Family
ID=57007695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707705UA SG11201707705UA (en) | 2015-04-01 | 2016-04-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| SG10201909173P SG10201909173PA (en) | 2015-04-01 | 2016-04-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909173P SG10201909173PA (en) | 2015-04-01 | 2016-04-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10508149B2 (enExample) |
| EP (2) | EP3277321B1 (enExample) |
| JP (1) | JP6949717B2 (enExample) |
| KR (1) | KR102711906B1 (enExample) |
| CN (2) | CN107847589B (enExample) |
| AU (1) | AU2016242964C1 (enExample) |
| DK (1) | DK3277321T3 (enExample) |
| EA (1) | EA201792184A1 (enExample) |
| ES (1) | ES2988351T3 (enExample) |
| FI (1) | FI3277321T3 (enExample) |
| HR (1) | HRP20241498T1 (enExample) |
| HU (1) | HUE068448T2 (enExample) |
| IL (2) | IL283006B2 (enExample) |
| LT (1) | LT3277321T (enExample) |
| MA (1) | MA41867B1 (enExample) |
| MX (1) | MX383216B (enExample) |
| PL (1) | PL3277321T3 (enExample) |
| PT (1) | PT3277321T (enExample) |
| RS (1) | RS66030B1 (enExample) |
| SG (2) | SG11201707705UA (enExample) |
| SI (1) | SI3277321T1 (enExample) |
| SM (1) | SMT202400420T1 (enExample) |
| WO (1) | WO2016161270A1 (enExample) |
| ZA (1) | ZA201706740B (enExample) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3409278B8 (en) | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| RS59878B1 (sr) | 2015-03-23 | 2020-03-31 | Bayer Pharma AG | Anti-ceacam6 antitela i njihova primena |
| IL283006B2 (en) * | 2015-04-01 | 2023-10-01 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP4086264B1 (en) | 2015-05-18 | 2023-10-25 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| TWI895621B (zh) | 2016-05-27 | 2025-09-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| US11155624B2 (en) * | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CN108101989A (zh) * | 2016-11-24 | 2018-06-01 | 复旦大学 | 针对人tim-3的全人源单域抗体及应用 |
| WO2018106529A1 (en) * | 2016-12-08 | 2018-06-14 | Eli Lilly And Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| SG10201913083SA (en) * | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| US11345753B2 (en) | 2017-02-27 | 2022-05-31 | Jiangsu Hengrui Medicine Co., Ltd. | TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof |
| KR102769634B1 (ko) | 2017-04-27 | 2025-02-19 | 테사로, 인코포레이티드 | 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도 |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| KR20200021087A (ko) | 2017-06-22 | 2020-02-27 | 노파르티스 아게 | Cd73에 대한 항체 분자 및 이의 용도 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| JP2020525483A (ja) * | 2017-06-27 | 2020-08-27 | ノバルティス アーゲー | 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用 |
| CN111163798A (zh) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | 用于抗lag-3抗体的给药方案及其用途 |
| US11214615B2 (en) | 2017-07-28 | 2022-01-04 | Phanes Therapeutics, Inc. | Anti-TIM-3 antibodies and uses thereof |
| KR20200044899A (ko) | 2017-08-28 | 2020-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료 및 진단을 위한 tim-3 길항제 |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| RU2020119578A (ru) | 2017-11-16 | 2021-12-17 | Новартис Аг | Комбинированные терапии |
| SG11202005005YA (en) | 2017-11-30 | 2020-06-29 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| EP3737408A1 (en) | 2018-01-08 | 2020-11-18 | Novartis AG | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031B2 (en) | 2018-01-31 | 2025-10-09 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| US11807683B2 (en) | 2018-04-12 | 2023-11-07 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding TIM-3 and use thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CA3097741A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Ｂｃｍａに対する結合分子及びその使用 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| PL3820573T3 (pl) | 2018-07-10 | 2024-02-19 | Novartis Ag | Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2) |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| CN112512582B (zh) | 2018-08-20 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | Tim-3抗体在制备治疗肿瘤的药物中的用途 |
| AU2019330702A1 (en) | 2018-08-28 | 2021-04-08 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-TIM3 antibody pharmaceutical composition and use thereof |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| US11638730B2 (en) | 2018-09-26 | 2023-05-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| CN118994103A (zh) | 2018-10-03 | 2024-11-22 | 特沙诺有限公司 | 尼拉帕利盐 |
| CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020119719A1 (en) * | 2018-12-12 | 2020-06-18 | Wuxi Biologics (Shanghai) Co. Ltd. | Anti-tim-3 antibodies and uses thereof |
| BR112021007968A2 (pt) | 2018-12-19 | 2021-09-08 | Bayer Aktiengesellschaft | Combinação farmacêutica de anticorpos anti-ceacam6 e tim3 |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| WO2020128894A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| KR20210108422A (ko) | 2018-12-21 | 2021-09-02 | 노파르티스 아게 | IL-1β 결합 항체의 용도 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| CN113227137A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途 |
| IL282838B2 (en) | 2018-12-21 | 2025-05-01 | Valerio Therapeutics | Conjugated nucleic acid molecules and their uses |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| CA3133460A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| WO2020192709A1 (en) * | 2019-03-27 | 2020-10-01 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific polypeptide complexes |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| AU2020296124A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIM-3 antibodies |
| WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| CA3151667A1 (en) | 2019-08-29 | 2021-03-04 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| WO2021053490A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
| MX2022004766A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Terapias combinadas con venetoclax e inhibidores de tim-3. |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| EP4077388A1 (en) | 2019-12-18 | 2022-10-26 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| BR112022012310A2 (pt) | 2020-01-17 | 2022-09-06 | Novartis Ag | Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica |
| US20230140694A1 (en) * | 2020-04-14 | 2023-05-04 | GlaxoSmithKline Intellectual Property Developement Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| CA3206549A1 (en) | 2021-01-29 | 2022-08-04 | Frederick G. Vogt | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022223048A1 (en) * | 2021-04-23 | 2022-10-27 | Suzhou Neologics Bioscience Co. , Ltd. | Tim-3-targetting antibodies and uses thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| IL310773A (en) | 2021-09-02 | 2024-04-01 | Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts | Anti-CECAM6 antibodies with reduced side effects |
| US20240294926A1 (en) | 2021-12-16 | 2024-09-05 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| JP2025501238A (ja) | 2021-12-30 | 2025-01-17 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法 |
| JP2025504908A (ja) | 2022-01-28 | 2025-02-19 | アイオバンス バイオセラピューティクス，インコーポレイテッド | サイトカイン関連腫瘍浸潤リンパ球組成物及び方法 |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| KR20250089492A (ko) | 2022-11-07 | 2025-06-18 | 네오이뮨텍, 인코퍼레이티드 | 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법 |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024211551A1 (en) | 2023-04-06 | 2024-10-10 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| WO2001057219A2 (en) | 2000-02-02 | 2001-08-09 | Schering Corporation | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20030103985A1 (en) * | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| US20030229910A1 (en) * | 2002-04-17 | 2003-12-11 | Richard Metz | Short fragment homologous replacement to provide BSE resistant cattle |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US7824681B2 (en) | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| MX373170B (es) | 2006-09-08 | 2020-04-22 | Amgen Inc | Variantes de la familia il-1. |
| RS51780B (sr) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CA2721231C (en) | 2008-04-14 | 2015-10-06 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| CA2843158A1 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR102038310B1 (ko) | 2011-11-16 | 2019-11-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 ｉｌ-36ｒ 항체 |
| CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| AU2013206788B2 (en) | 2011-12-28 | 2017-11-30 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
| MY177331A (en) * | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| CA2905940A1 (en) | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized, anti-n2 antibodies |
| ES2926773T3 (es) | 2013-03-15 | 2022-10-28 | Novo Nordisk As | Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular |
| PT2992017T (pt) * | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| EP3215532B1 (en) | 2014-11-06 | 2019-10-23 | F.Hoffmann-La Roche Ag | Anti-tim3 antibodies and methods of use |
| GB201421430D0 (en) | 2014-12-02 | 2015-01-14 | Medimmune Llc | Antibodies to Adam17 and uses thereof |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| IL283006B2 (en) | 2015-04-01 | 2023-10-01 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| PL3303386T3 (pl) | 2015-06-05 | 2025-03-03 | Genentech, Inc. | Przeciwciała anty-tau i sposoby zastosowania |
| PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
| MY198562A (en) | 2015-11-03 | 2023-09-05 | Janssen Biotech Inc | Antibodies specifically binding pd-1 and their uses |
| IL321475A (en) | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| SG10201913083SA (en) * | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2016
- 2016-04-01 IL IL283006A patent/IL283006B2/en unknown
- 2016-04-01 KR KR1020177031599A patent/KR102711906B1/ko active Active
- 2016-04-01 HU HUE16774301A patent/HUE068448T2/hu unknown
- 2016-04-01 WO PCT/US2016/025532 patent/WO2016161270A1/en not_active Ceased
- 2016-04-01 SM SM20240420T patent/SMT202400420T1/it unknown
- 2016-04-01 DK DK16774301.2T patent/DK3277321T3/da active
- 2016-04-01 JP JP2017550931A patent/JP6949717B2/ja active Active
- 2016-04-01 PL PL16774301.2T patent/PL3277321T3/pl unknown
- 2016-04-01 AU AU2016242964A patent/AU2016242964C1/en active Active
- 2016-04-01 EP EP16774301.2A patent/EP3277321B1/en active Active
- 2016-04-01 ES ES16774301T patent/ES2988351T3/es active Active
- 2016-04-01 CN CN201680031744.7A patent/CN107847589B/zh active Active
- 2016-04-01 CN CN202210219598.8A patent/CN114539409B/zh active Active
- 2016-04-01 MX MX2017012429A patent/MX383216B/es unknown
- 2016-04-01 PT PT167743012T patent/PT3277321T/pt unknown
- 2016-04-01 LT LTEPPCT/US2016/025532T patent/LT3277321T/lt unknown
- 2016-04-01 EP EP24193943.8A patent/EP4442712A3/en active Pending
- 2016-04-01 SG SG11201707705UA patent/SG11201707705UA/en unknown
- 2016-04-01 US US15/563,924 patent/US10508149B2/en active Active
- 2016-04-01 HR HRP20241498TT patent/HRP20241498T1/hr unknown
- 2016-04-01 EA EA201792184A patent/EA201792184A1/ru unknown
- 2016-04-01 SG SG10201909173P patent/SG10201909173PA/en unknown
- 2016-04-01 MA MA41867A patent/MA41867B1/fr unknown
- 2016-04-01 RS RS20241112A patent/RS66030B1/sr unknown
- 2016-04-01 SI SI201631851T patent/SI3277321T1/sl unknown
- 2016-04-01 FI FIEP16774301.2T patent/FI3277321T3/fi active
-
2017
- 2017-09-18 IL IL254559A patent/IL254559B2/en unknown
- 2017-10-06 ZA ZA2017/06740A patent/ZA201706740B/en unknown
-
2019
- 2019-10-17 US US16/655,939 patent/US11352427B2/en active Active
-
2022
- 2022-05-03 US US17/661,841 patent/US20220363759A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283006A (en) | Antibodies directed against T-cell immunoglobulin and myokine protein 3 (T-IM-3) | |
| IL266230A (en) | Antibodies directed against t-cell immunoglobulin and mucin protein 3 (tim-3) | |
| ZA202000113B (en) | Anti-ctla-4 antibodies and uses thereof | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| IL323534A (en) | Anti-PD-L1 antibody and its uses | |
| IL276950B1 (en) | Anti-CD73 antibodies and their uses | |
| IL272218A (en) | ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL265625A (en) | Antibodies activated against ctla-4 and their uses | |
| ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
| ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
| SG10201911972QA (en) | Antibodies against tim3 and uses thereof | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| EP3325513A4 (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| SG10202109689QA (en) | Humanized anti-pacap antibodies and uses thereof | |
| ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL274202A (en) | Antibodies against Glyco-Moc1 and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| IL266059A (en) | Anti-rankl antibodies and their uses | |
| HK40011740A (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| EP3307304A4 (en) | Immunoglobulin fusion proteins and uses thereof |